(Jerusalem Composer) President Pfizer, US Pharmaceutical Company, believesIn the campaign to fight crown disease, vaccination every year will be more ideal than frequent vaccination.
The company's president Aberle the day before yesterday (January 22) was interviewed by Israeli N12 TV station that it was not the most ideal way every four or five months."What I hope is that we have a vaccine that can make you inoculate once a year. Once once a year, it is easier to persuade people to take over. It is easier for people to remember (when to take vaccination). From the perspective of public health,This is an ideal arrangement. "
He also said that Pfizer is studying a vaccine that can resist Omikon and other coronary viruses at the same time. Such vaccines will be a good plan to solve the epidemic situation.Essence
Modner wants to develop coronary disease and influenza vaccine at the same time
In response to the idea of vaccination once a year, another vaccine producerLange, co -founder of Modner, also recently revealed that Modner hopes to develop a vaccine and at the same time resist crown disease and influenza virus to facilitate and encourage people to vaccinate each year.
According to him, this vaccine for crown diseases, influenza, and respiratory tract fusion viruses (RSV) is expected to be launched next year, so that people can be protected by only one dose of one dose.
The existing Pfizer -Biontech vaccine has shown that it can effectively prevent Omikon cause severe illnesses and reduce risk of death, but it is poor to prevent the effect of this high infectious virus transmission.Due to the great increase in new cases, many countries have launched the operation of inoculation, which also shorten the interval between the second agent and additional agent to enhance the antibodies in the people.
It is expected to be mass -produced in March for the Omikon vaccine
Aberle pointed out that Pfizer and partner Biontech is developingOmikon's vaccine, as well as an old vector of vaccine components, but at the same time, it can cope with Omikon's vaccine, which is expected to start a large number of production in March as soon as possible.
For the effect of adding agents, the American Disease Control and Prevention Center quoted the results of three studies last Friday that the third dose of the messenger of the nucleotic acid (mRNA) crown disease is against OmikonIt can play a key role, and the effectiveness of hospitalization after preventing infection can reach 90%.
The preliminary data of the Experiment of the Sherba Medical Center in Israel showed a preliminary data on the 17th of this month that the fourth dose of coronary vaccine will help improve the level of antibody, but it is still not enough to effectively prevent Omikon Rong RongEssenceNevertheless, the center still recommends that high -risk groups inoculate two doses, that is, the fourth shot should be taken.
